News

The participants included more than 2,000 pregnant individuals at higher risk of preeclampsia.

AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.

Dr. Christine Rauscher details immunotherapy for seasonal allergies, which affect roughly 20 millions adults in the US

Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.

The Lumipulse G β-Amyloid Ratio is the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimers disease.

Study investigators used data from midlife checkpoints and late life checkpoints for participants without heart failure.

Data show half of all eyes with CRVO were still being treated at 36-months.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

Treatment delay and steroid usage were both associated with worse improvements in long term BVA and CST in patients with RVO-related macular edema.

Data from a pivotal trial presented at ATTD 2022 demonstrate the use of the iLet Bionic Pancreas was associated with significant improvements in HbA1c and TIR among a diverse study population of adults and children with type 1 diabetes compared with standard care.

Dr. Levine is joined by Dr. Sanjay Mathew to talk about some exciting treatments in the pipeline for psychiatric disorders.

In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.

Amid major national judicial and legislative deliberation on reproductive health care access, the Brigham and Women's and Harvard University expert joins to discuss the clinical matters of abortion.

These data further elucidate the relationship between mental health and diabetic retinopathy.

However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.

A new assessment from ARVO 2022 showed methodology to predict one-year treatment response to treat-and-extend ranibizumab at 1 year.

The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

Patients with DR had an average interval between anti-VEGF injections of 70 days, compared to 54 days for RVO patients and 55 days for wetAMD patients.

Expert gynecologist Dr. Deborah Bartz addresses the clinical implications of an abortion ban if Roe v. Wade is overturned.

There was a greater proportion of the undetected (19%) or previously detected (23%) dysplasia group that had concurrent primary sclerosing cholangitis compared to only 3% of the group without dysplasia.

New data from phase 3 of the ORCA-2 trial found that adults treated 3 times daily with cytisinicline were more inclined to quit smoking cigarettes.

The risk of cSCC was significantly higher in patients who received treatment for actinic keratosis.

New-onset diarrhea is common among inpatients and residents of long-term care facilities.

The Elevatum trial will assess the newly approved ophthalmic drug in patients from African American, Hispanic, Latin American, and Indigenous communities.

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.

The estimated median duration of ≥1 line gained was greater than 9 hours on both study day 1 and day 30 in patients with presbyopia treated with the study agent.